FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
19 Nov 2021
19 Nov 2021
Historique:
received:
21
04
2021
accepted:
22
09
2021
entrez:
20
11
2021
pubmed:
21
11
2021
medline:
21
11
2021
Statut:
epublish
Résumé
Uterine sarcomas are rare but deadly malignancies without effective treatment. Immunotherapy is a promising new approach to treat these tumors but has shown heterogeneous effects in sarcoma patients. With the goal of identifying key factors for improved patient treatment, we characterized the tumor immune landscape in 58 uterine sarcoma cases with full clinicopathological annotation. Immune cell characterization revealed the overall prevalence of FOXP3+ cells and pro-tumor M2-like macrophages. Hierarchical clustering of patients showed four tumor type-independent immune signatures, where infiltration of FOXP3+ cells and M1-like macrophages associated with favorable prognosis. High CD8+/FOXP3+ ratio in UUS and ESS correlated with poor survival, upregulation of immunosuppressive markers, extracellular matrix (ECM)-related genes and proteins, and YAP activation. This study shows that uterine sarcomas present distinct immune signatures with prognostic value, independent of tumor type, and suggests that targeting the ECM could be beneficial for future treatments.
Identifiants
pubmed: 34799669
doi: 10.1038/s41698-021-00236-6
pii: 10.1038/s41698-021-00236-6
pmc: PMC8604926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Subventions
Organisme : Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet)
ID : 141082
Organisme : Cancerfonden (Swedish Cancer Society)
ID : 2017/473
Organisme : Cancerfonden (Swedish Cancer Society)
ID : 200169F
Organisme : Cancerfonden (Swedish Cancer Society)
ID : 201128Pj
Organisme : Cancerfonden (Swedish Cancer Society)
ID : 2018/858
Organisme : Karolinska Institutet (Karolinska Institute)
ID : 2-5586/2017
Organisme : Barncancerfonden (Swedish Childhood Cancer Foundation)
ID : TJ2019-0100
Organisme : Stiftelsen Clas Groschinskys Minnesfond (Clas Groschinski's Memorial Foundation)
ID : M21139
Organisme : Vetenskapsrådet (Swedish Research Council)
ID : 2019-01541
Informations de copyright
© 2021. The Author(s).
Références
Int J Mol Sci. 2018 Nov 20;19(11):
pubmed: 30463366
J Cancer. 2017 Jul 5;8(11):2018-2025
pubmed: 28819402
Oncoimmunology. 2016 Feb 18;5(5):e1134412
pubmed: 27467953
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Arthritis Rheum. 2008 Aug;58(8):2228-35
pubmed: 18668576
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
FASEB J. 2008 Oct;22(10):3500-8
pubmed: 18587005
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Gynecol Oncol. 2010 Jan;116(1):131-9
pubmed: 19853898
Oncogene. 2010 Jul 22;29(29):4121-9
pubmed: 20498631
Eur J Immunol. 2011 Mar;41(3):716-25
pubmed: 21312192
Front Immunol. 2015 Apr 15;6:171
pubmed: 25926835
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Cancer Immunol Immunother. 2014 Sep;63(9):869-76
pubmed: 25063364
Oncotarget. 2016 May 24;7(21):30094-108
pubmed: 27129148
Histopathology. 2009 Feb;54(3):355-64
pubmed: 19236512
Cell. 2008 Aug 8;134(3):392-404
pubmed: 18692464
Cancer Res. 2018 May 15;78(10):2705-2720
pubmed: 29490948
Am J Cancer Res. 2015 Dec 15;6(1):27-37
pubmed: 27073720
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Med Mol Morphol. 2018 Mar;51(1):13-20
pubmed: 28687956
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570276
Cell Rep. 2018 Oct 30;25(5):1304-1317.e5
pubmed: 30380420
Jpn J Pharmacol. 1984 Sep;36(1):7-13
pubmed: 6503049
Cancers (Basel). 2021 Jan 19;13(2):
pubmed: 33478080
Cancer Immunol Immunother. 2014 Jun;63(6):545-57
pubmed: 24658839
Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v2-4
pubmed: 18784131
Curr Opin Oncol. 2013 Sep;25(5):546-52
pubmed: 23942299
Cancer Immunol Res. 2020 Jul;8(7):952-965
pubmed: 32265228
Int J Womens Health. 2017 Aug 31;9:597-606
pubmed: 28919822
Lancet Oncol. 2009 Dec;10(12):1188-98
pubmed: 19959075
Clin Cancer Res. 2017 Mar 1;23(5):1274-1285
pubmed: 28232476
J Surg Oncol. 2018 Jul;118(1):68-76
pubmed: 29878369
Front Pharmacol. 2020 Oct 15;11:557429
pubmed: 33178014
Nat Commun. 2021 May 31;12(1):3256
pubmed: 34059671
Clin Cancer Res. 2019 Apr 1;25(7):2155-2165
pubmed: 30617134
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
Cancer Immunol Immunother. 2010 May;59(5):653-61
pubmed: 19908042
Oncogene. 2017 Mar 2;36(9):1232-1244
pubmed: 27546622
Clin Cancer Res. 2020 Aug 1;26(15):4018-4030
pubmed: 32332015
PLoS One. 2013 Nov 15;8(11):e80908
pubmed: 24260507